The Allogeneic CD4⁺ T-Cell-Mediated Graft-versus-Leukemia Effect

References

• Goldman J. M. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Experimental Hematology Today. Recent advances and future directions in bone marrow transplantation, S. J. Baum, G. W. Santos, F. Takaku. Springer Verlag, New York 1987; 94
   Google Scholar
• Talpaz M., Kantarjian M., Kurzrock R., Gutterman J. Update on therapeutic options for chronic myelogenous leukemia. Semin Hem 1990; 27(suppl 4)31–36
   PubMedGoogle Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. ‐J., Rimm A. A., Ringden O., Rozman C., Speck B., Truitt R. L., Zwaan F. E., Bortin M. M. Graft‐versus‐leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D., Storb R. Antileukemia effect of graft versus host disease in human recipients of allogeneic marrow graft. N. Engl J Med 1979; 300: 1068
   PubMed Web of Science ®Google Scholar
• Collins R. H., Jr., Rogers Z. R., Bennett M., Kumar V., Niekein A., Fay J. W. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft‐versus‐leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391
   PubMed Web of Science ®Google Scholar
• Goldman J. M., Gale R. P., Horowitz M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T‐cell depletion. Ann Intern Med 1988; 108: 806–814
   PubMed Web of Science ®Google Scholar
• Martin P., Hansen J. A., Buchner C. D., et al. Effects of in vitro depletion of T‐cells in HLA identical allogeneic marrow grafts. Blood 1985; 66: 664–672
   PubMed Web of Science ®Google Scholar
• Apperley J. F., Jones L., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T‐cell depletion with Campath‐1 reduces the incidence of GVHD but may increase the risk of leukemia relapse. Bone Marrow Transplant 1986; 1: 53–68
   PubMed Web of Science ®Google Scholar
• Van Rhee F., Kolb H. ‐J. Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 1995; 2: 423
   PubMedGoogle Scholar
• Cullis J. O., Jiang Y. Z., Schwarer A. P., Hughes T. P., Barrett A. J., Goldman J. M. Donor leukocyte infusion in the treatment of chronic myeloid leukaemia in relapse following allogenic bone marrow transplantation. Blood 1992; 19: 1379–1381
   Google Scholar
• Jiang Y. Z., Cullis J. O., Kanfer E. J., Goldman J. M., Barret A. J. T‐cell and NK cell mediated graft versus leukemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplantation 1993; 11: 133–138
   PubMed Web of Science ®Google Scholar
• Papadopoulos E., Ladanyi M., Emanuel D., et al. Infusion of donor leukocytes to treat EB V associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–1191
   PubMed Web of Science ®Google Scholar
• Tricot G., Vesole D., Jagannath S., et al. Graft‐versus‐myeloma effect: proof of principle. Blood 1996; 87: 1196–1198
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Lokhorst H. M., Dekker A. W., Nieuwenhuis H. K., Petersen E. J. Graft‐versus‐myeloma effect in two cases. Lancet 1996; 347: 800–801
   PubMed Web of Science ®Google Scholar
• Eibl B., Schwaighofer H., Nachbaur D., et al. Evidence of a graft‐versus tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508
   PubMed Web of Science ®Google Scholar
• Nimer S. D., Giorgi J., Gajewski J. L., Ku N., Schiller G. J., Lee K., Territo M., Ho W., Feig S., Selch M., Isacescu V., Reichert T. A., Champlin R. E. Selective depletion of CD8+ cells for prevention of graft‐versus‐host disease after bone marrow transplantation. Transplantation 1994; 57: 82
   PubMed Web of Science ®Google Scholar
• Giralt S., Hester J., Huh Y., Hirsch‐Ginsberg C., Rondón G., Seong D., Lee M., Gajewski J., Van Besien K., Khouri I., Mehra R., Przepiorka D., Körbling M., Talpaz M., Kantarjian H., Fischer H., Deisseroth A., Champlin R. CD8‐depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337
   PubMed Web of Science ®Google Scholar
• Palathumpat V., Dejbakhsh‐Jones S., Strober S. The role of purified CD8+ T‐cells in graft‐versus‐leukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation 1995; 60: 355
   PubMed Web of Science ®Google Scholar
• Herrera C., Martin C., Garcia‐Castellano J. M., Roman J., Alvarez M. A., Flores R., Garcia M. J., de la Torre M. J., Sanchez J., Marlines F., Gomez P., Torres A. Prevention of GVHD by selective CD4+ T‐cell depletion plus adjustment of the CD8+ cell content in donor bone marrow. (Abstract). Blood 1995; 86(suppl 1)571a
   Google Scholar
• Jiang Y. Z., Barrett A. J., Goldman J. M., Mavroudis D. A. Association of Natural Killer cell immune recovery with a graft‐vs. ‐leukemia effect independent of graft vs. host disease after allogeneic bone marrow transplantation. Ann Hematol 1996, (in press)
   Web of Science ®Google Scholar
• Glass B., Uharek L., Zeis M., Loeffler H., Mueller‐Ruchholtz W., Gassmann W. Graft‐versus‐leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br. J. Haematol. 1996; 93: 412
   PubMed Web of Science ®Google Scholar
• Glass B., Uharek L., Gassmann W., Focks B., et al. Graft‐versus‐leukemia activity after bone marrow transplantation does not require graft‐versus‐host disease. Ann Hematol 1992; 64: 255–259
   PubMed Web of Science ®Google Scholar
• Barrett A. J., Malkovska V. Annotation: Graft‐versus‐leukemia: understanding and using the alloimmune response to treat hematological malignancies. Br J Haematol 1996; 93: 754
   PubMed Web of Science ®Google Scholar
• Mavroudis D. A., Barrett A. J. The graft versus leukemia effect. Curr Opin Hematol 1996; 3: 423–429
   PubMedGoogle Scholar
• Truitt R. L., Johnson B. D. Review: Principles of graft versus leukemia reactivity. Biology of blood and marrow transplantation 1995; 1: 61–68
   PubMedGoogle Scholar
• Antin J. H. Review: Graft‐versus‐leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273
   PubMed Web of Science ®Google Scholar
• Barrett A. J., Jiang Y. Z. Review: Immune response to chronic myeloid leukemia. Bone Marrow Transplantation 1992; 9: 305–311
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Heslop H. E. Graft‐versus‐leukemia effects after marrow transplantation in man. Bailliere's Clinical Hematology Minimal Residual Disease in Leukemia, S. J. Proctor. Baillere Tindall, London 1991; 4: 727
   Google Scholar
• Krenger W., Ferrara J. L. M. Graft versus host disease and the Th1/Th2 paradigm. Immunol Res 1996; 15: 50–73
   PubMed Web of Science ®Google Scholar
• Kourilsky P., Claverie J. M. MHC‐antigen interaction: what does the T‐cell receptor see?. Adv Immunol 1989; 45: 107
   PubMed Web of Science ®Google Scholar
• Janaway C. A. Review: The role of CD4 in T‐cell activation: activation molecule or corecepor?. Immunol Today 1989; 10: 234–238
   PubMedGoogle Scholar
• Gribben J., Guinan E., Boussiotis V., et al. Complete blockade of B7 family‐mediated co‐stimulation is necessary to induce human alloantigen specific anergy: a method to ameliorate graft versus host disease and extend the donor pool. Blood 1996; 87: 4887–4893
   PubMed Web of Science ®Google Scholar
• Blazar B., Taylor P., Panoskaltsis‐Mortari A., et al. Co‐blockade of the LFA‐1:ICAM and CD28/CTLA4:B7 pathway is a highly effective means of preventing acute lethal graft versus host disease induced by fully major histocompatibility complex‐disparate donor grafts. Blood 1995; 85: 2607–2618
   PubMed Web of Science ®Google Scholar
• Meuer S. C., Roux M. M., Schraven B. The alternative pathway of T‐cell activation: biology, pathophysiology and prospective for immunopharmacology. Clinical Immunol. and Immunopath. 1989; 50: 133–139
   Google Scholar
• Amlot P. L., Tahami F., Chinn D., Rawlings E. Activation antigen expression on human T‐cells. Analysis by two‐colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 1996; 105: 176–182
   PubMed Web of Science ®Google Scholar
• Turner J., Dockrell H. M. Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T‐cells in vitro. Immunology 1996; 87: 339–342
   PubMed Web of Science ®Google Scholar
• Hamblin A. S. Lymphokines, D. Male, D. Rickwood. IRL Press, Oxford 1988
   Google Scholar
• Jiang Y. Z., Barrett A. J. Cellular and cytokine mediated effects of CD4+ lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol 1995; 23: 1167
   PubMed Web of Science ®Google Scholar
• Oettel K. R., Wesly O. H., Albertini M. R., Hank J. A., Iliopolis O., Sosman J. A., Voelkerding K., Wu S., Clark S. S., Sondel P. M. Allogeneic T‐cell clones able to selectively destroy Philadelphia chromosome‐bearing (Ph1+) human leukemia lines can also recognize Phi‐ cells from the same patient. Blood 1994; 83: 3390
   PubMed Web of Science ®Google Scholar
• Faber L., van Luxemberg‐Heijs S., Veenhof W., et al. Generation of CD4+ cytotoxic T‐lymphocyte clones from a patient with severe graft versus host disease after allogeneic gone marrow transplantation: implications for graft versos leukemia reactivity. Blood 1995; 86: 2821–2828
   PubMed Web of Science ®Google Scholar
• Grogg D., Hahn S., Erb P. CD4+ T‐cell‐mediated killing of major histocompatibility complex class‐II‐positive antigen‐presenting cells. III. CD4+ cytotoxic T‐cells induce apoptosis of APC. Eur J Immunol 1992; 22: 267
   PubMed Web of Science ®Google Scholar
• Stadler T. Fas antigen is the major target molecule for CD4+ mediated cytotoxicity. J Immunol 1994; 152: 1127–1134
   PubMed Web of Science ®Google Scholar
• Zychlinsky A., Zheng L. M., Liu C. C., Young J. D. E. Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J Immunol 1991; 146: 393
   PubMed Web of Science ®Google Scholar
• Susskind B., Shornick M. D., Iannotti M. R., Duffy B., Mehrotra nee Tanden P., Siegel J. P., Mohanakumar T. Cytolytic effector mechanisms of human CD4+ cytotoxic T‐lymphocytes. Human Immunol. 1996; 45: 64
   PubMed Web of Science ®Google Scholar
• Ju S. T., Cui H., Panka D. J., Ettinger R., Marshak‐Rothstein A. Participation of target fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T‐cells. Pro Natl Acad Sci USA 1994; 91: 4185
   PubMed Web of Science ®Google Scholar
• Kagi D., Vignaux F., Ledermenn B., Burki K., Depraetere V., Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T‐cell‐mediated cytotoxicity. Science 1994; 265: 528
   PubMed Web of Science ®Google Scholar
• Brossart P., Bevan M. J. Selective activation of Fas/Fas ligand‐mediated cytotoxicity by a self peptide. J Exp Med 1996; 183: 2449–2458
   PubMed Web of Science ®Google Scholar
• Townsend R. M., Paterson A., Hsieh M. H., Korngold R. Studies of the graft‐versus‐myeloid leukemia responses following murine bone marrow transplantation. (abstract). Blood 1996; 88(suppl 1)244a
   Google Scholar
• Korngold R., Sprent J. T‐cell subsets and graft versus host disease. Transplantation 1987; 44: 335–339
   PubMed Web of Science ®Google Scholar
• O'Kunewick J., Kociban D., Machen L., Buffo M. Effect of selective donor T‐cell depletion on the graft‐versus‐leukemia reaction in allogeneic marrow transplantation. Transplant. Proceeding 1992; 24: 2998
   PubMed Web of Science ®Google Scholar
• Truitt R. L., Atasoylu A. A. Contribution of CD4+ and CD8+ T‐cells to graft‐versus‐host disease and graft‐versus‐leukemia reactivity after transplantation of MHC‐compatible bone marrow. Bone Marrow Transplant 1991; 8: 51
   PubMed Web of Science ®Google Scholar
• Jiang Y. Z., Kanfer E., MacDonald M., Cullis J. O., Goldman J. M., Barrett A. J. Graft versus leukemia effect following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes to host leukemia cells. Bone Marrow Transplantation 1991; 8: 253–258
   PubMed Web of Science ®Google Scholar
• Bunjes D., Theobald M., Hertenstein B., et al. Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host reactive interleukin‐2 secreting T‐helper cells. Bone Marrow Transplant 1995; 15: 713–719
   PubMed Web of Science ®Google Scholar
• Mackinnon S., Papadopoulos E. B., Carabsi M., Reich L., Collins N. H., Boulad F., Castro‐Malaspina H., Childs B. H., Gillio A. P., Kernan N. A., Small T. N., Young J. W., O'Reilly R. J. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of CML after bone marrow transplantation: separation of graft versus leukemia responses from graft versus host disease. Blood 1995; 86: 1261
   PubMed Web of Science ®Google Scholar
• Moss P. A. H., Bell J. I. The human T‐cell receptor repertoire. T‐cell Receptors, J. I. Bell, M. J. Owen, Simpson. Oxford University Press, Oxford 1995
   Google Scholar
• Pinet V., Malnati M. S., Long E. O. Two processing pathways for the MHC class II restricted presentation of exogenous influenza virus antigen. J Immunol. 1994; 152: 4852–4860
   PubMed Web of Science ®Google Scholar
• Gale R. P. Graft versus host disease. Immunology Review 1985; 88: 19–212
   Web of Science ®Google Scholar
• Naume B., Gately M., Espevik T. A comparative study of IL12, IL2 and IL7 induced effectors on immunomagnetically purified CD56 NK cells. J Immunol 1992; 148: 2429–2436
   PubMed Web of Science ®Google Scholar
• Lamont A. G., Adorini L. IL‐12: a key cytokine in immune regulation. Immunol Today 1996; 17: 214–217
   PubMedGoogle Scholar
• Niederwieser D., Aubock J., Troppmair J., et al. IFN‐mediated induction of MHC antigen expression on human keratinocytes nd its influence on in vitro alloimmune responses. J Immunol 1988; 140: 2556–2564
   PubMed Web of Science ®Google Scholar
• Vanky F., Hising C., Sjowalk K., Larsson B., Rodriguez L., Orre L., Klein E. Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon‐r and tumor necrosis factor‐a treatment of tumor cells potentiates their interaction with autologous blood lymphocytes. Cancer Immunol Immunother. 1995; 41: 217–226
   PubMed Web of Science ®Google Scholar
• Oyaizu N., McCloskey T. W., Than S., Hu R., Kalyanaraman V. S., Pahwa S. Cross‐linking of CD4 molecules up‐regulates Fas antigen expression in lymphocytes by inducing interferon‐gamma and tumor necrosis factor‐alpha secretion. Blood 1994; 84: 2622–2631
   PubMed Web of Science ®Google Scholar
• Cohen J. J. Apoptosis. Immuno Today 1993; 14: 126–130
   PubMedGoogle Scholar
• Nuchlern J. G., Biddison W. E., Klausner R. D. Class II MHC moleculaes can use the endogenous pathway of antigen presentation. Nature 1990; 343: 74
   PubMed Web of Science ®Google Scholar
• Laughlin M. J., Kurtzberg J., Weinhold K., Ferrari G., Pilgrim A., Gelber C., Nair S., Gilboa E., Smith C. A., Martinek L., DeOliveria D., Lyerly H. K. Generation of T‐lymphocyte clones specific for acute lymphoblastic leukemia (ALL) via dendritic cell, (abstract). Blood 1996; 88(suppl 1)375a
   Google Scholar
• Falkenburg J. H. F., van Bergen C. A. M., Smit W. M., Willemze R. Induction of apoptic death of CD34+ chronic myeloid leukemia precursor cells by CD4+ T‐cells. (abstract). Blood 1996; 88(suppl 1)243a
   Google Scholar
• Jiang Y. Z., Mavroudis D. A., Dermime S., Hensel N. F., Couriel D., Molldrem J., Barrett A. J. Alloreactive CD4+ T‐lymphocytes can exert cytotoxicity to CML cells processing and presenting exogenous antigen. Br J Hematol 1996; 93: 606
   PubMed Web of Science ®Google Scholar
• Munker R., Lubbert M., Yonehara S., Tuhnitz A., Mertelsmann R., Wilmanns W. Expression of the fas antigen on primary human leukemia cells. Ann Hematol 1995; 70: 15
   PubMed Web of Science ®Google Scholar
• Zoumbos N. C., Djeu J. Y., Young N. S. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 1984; 133: 769
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Williams D. E., Lu L., Cooper S., Anderson S. L., Beyer G. S., Hoffman R., Rubin B. Y. The supressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon‐gamma. J Immunol 1986; 136: 4487
   PubMed Web of Science ®Google Scholar
• Munker R., Koeffler P. In vitro action of tumor necrosis factor on myeloid leukemia cells. Blood 1987; 69: 1102–1108
   PubMed Web of Science ®Google Scholar
• Perreault C., Decary F., Brochu S., Gyger M., Belanger R., Roy D. C. Minor histocompatibility antigens. Blood 1990; 76: 1269
   PubMed Web of Science ®Google Scholar
• Goulmy E. Minor histocompatibility antigens in man and their role in transplantation. Transplantation Reviews 2, P. J. Morris, N. L. Tilney. Sauders, Philadelphia, PA 1988; 29
   Google Scholar
• Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA‐identical donors and recipients and the development of GVHD after allogeneic BMT. N Engl J Med 1996; 334: 281–285
   PubMed Web of Science ®Google Scholar
• ten Bosch G. J. A., Joosten A. M., Kessler J. H., Melief C. J. M., Leeksma O. C. Recognition of BCR‐ABL positive leukemic blasts by human CD4+ T‐cells elicited by primary in vitro immunization with a BCR‐ABL breakpoint peptide. Blood 1996; 88: 3522
   PubMed Web of Science ®Google Scholar
• Bocchia M., Korontsvit T., Xu Q., Mackinnin S., Yan S. Y., Sette A., Scheinberg D. A. Specific human cellular immunity to bcr/abl oncogene‐derived peptides. Blood 1996; 87: 3587
   PubMed Web of Science ®Google Scholar
• Pawelec G., Max H., Haider T., Bruserud Ø., Merl A., da Silva P., Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA‐DR alleles and can be recognized by T‐cells found at low frequency in the repertoire of normal donors. Blood 1996; 88: 2118
   PubMed Web of Science ®Google Scholar
• Greco G., Fruci D., Accapezzato D., Barnaba V., Nisini R., Alimena G., Monteiusco E., Vigneti E., Butler R., Tanigaki N. Two bcr‐abl junction peptides bind HLA‐A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 695
   Google Scholar
• Dermime S., Molldrem J., Parker K. C., Jiang Y. Z., Mavroudis D. A., Hensel N. F., Couriel D., Mahony M., Barrett A. J. Human CD8+ T‐lymphocytes recognize the fusion region of BCR/ABL hybrid protein present in CML. (abstract). Blood 1995; 86(suppl 1)159a
   Google Scholar
• ten Bosch G. J. A., Toornvliet A. C., Friede T., Melief C. J. M., Leeskma O. C. Recognition of peptides corresponding to the joining region of p210 BCR‐ABL protein by human T‐cells. Leukemia 1995; 9: 1344
   PubMed Web of Science ®Google Scholar
• Delain M., Tiberghien P., Racadot E., Billot M., Pariset J., Chbod J., Cahn J. Y., Herve P. Variability of the alloreactivity T‐cell response to human leukemia blasts. Leukemia 1994; 8: 642
   PubMed Web of Science ®Google Scholar
• Molldrem J., Dermime S., Parker K., Jiang Y. Z., Mavroudis D. A., Hensel N. F., Fukushima P., Barrett A. J. Targeted T‐cell therapy for human leukemia: cytotoxic T‐lymphocytes specific for a peptide derived from proteinase‐3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450–2457
   PubMed Web of Science ®Google Scholar
• Chen W., Chatta K., Rubin W., Liggitt D. H., Kusunoki Y., Martin P., Cheever M. A. Polymorphic segments of CD45 can serve as targets for GVHD and GVL responses. (abstract). Blood 1995; 86: 622
   Web of Science ®Google Scholar
• Rooney C., Smith C., Loftin S., et al. Use of gene modified virus specific T Lymphocytes to control Epstein Barr virus related lymphoproliferation. Lancet 1995; 345: 9–13
   PubMed Web of Science ®Google Scholar
• Walter E., Greenberg P., Gilbert M., et al. Reconstitution of cellular immunity against cyomegalovirus in recipients of allogeneic bone marrow by transfer of T‐cell clones from the donor. N Engl J Med 1995; 333: 1038–1044
   PubMed Web of Science ®Google Scholar
• Mavroudis D. A., Jiang Y. Z., Hensel N. F., Lewalle P., Couriel D., Kreitman R. J., Pastart I., Barrett A. J. Selective depletion of alloreactivity against haplotype mismatched related individuals: A new approach to GVHD prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplantation 1996; 17: 793–799
   PubMed Web of Science ®Google Scholar
• Jiang Y. Z., Gordon A. A., Barrett A. J. The immunogeneicity of CML cells in CTL generation, (abstract). Swiss Medical J 1991; 121(43)147
   Google Scholar
• Dermime S., Mavroudis D. A., Jiang Y. Z., Hensel N. F., Molldrem J., Barrett A. J. Immune escape from a graft versus leukemia effect plays a role in the relapse of myelogenous leukemias following allogeneic bone marrow transplantation. (abstract). Blood 1996; 88: 610a
   Google Scholar
• Matulonis U. A., Dosiou C., Lamont C., Freeman G. J., Mauch P., Nadler L. M., Griffin J. D. Role of B7–1 in mediating an immune response to myeloid leukemia cells. Blood 1995; 85: 2507
   PubMed Web of Science ®Google Scholar
• Kapsenberg M. L., Stiekema F. E. M., Kalian A., Bos J. D., Roozemond R. C. The restrictive role of sialic acid in antigen presentation to a subset of human peripheral CD4+ T lymphocytes that requires antigen presenting dendritic cells. Eur J Immunol 1989; 19: 1829–1834
   PubMed Web of Science ®Google Scholar
• Ye Z., Gee A. P., Bowers W. E., Lamb L. S., Turner M. W., Henslee‐Downey P. J. In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34+ cells. Bone Marrow Transplant. 1996; 18: 997–1008
   PubMed Web of Science ®Google Scholar
• Yong J. W., Szabolcs P., Moore M. A. S. Identification of Dendritic cell colony‐forming units among normal human CD34+ bone marrow progenitors that are expanded by c‐kit‐ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony‐stimulating factor and tumor necrosis factor a. J Exp Med. 1995; 182: 111–1120
   Google Scholar
• Caux C., Massacrier C., Dezutter‐Dambuynt C., Vanbervliet B., Jacquet C., Schmitt D., Banchereau J. Human Dendritic Langerhans cells generated in vitro from CD34+ progenitor can prime naïve CD4+ T‐cells and process soluble antigen. J Immunol 1995; 15: 5427–5435
   Google Scholar
• Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91: 6458–6462
   PubMed Web of Science ®Google Scholar
• Datta A. R., Barrett A. J., Jiang Y. Z., Gordon A. A., Gumerais A., Madrigal A., Van Rhee F. Distinct T‐cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplantation 1994; 14: 517–524
   PubMed Web of Science ®Google Scholar
• Liu X., Chesnokova V., Forma S. J., Diamond D. J. Molecular analysis of T‐cell receptor repertoire in bone marrow transplant recipients: evidence for oligoclonal T‐cell expansion in graft‐versus‐host disease lesions. Blood 1996; 87: 3032
   PubMed Web of Science ®Google Scholar
• Howell C. D., Li J., Roper E., Kotzin B. L. Biased liver T‐cell receptor Vβ repertoire in a murine graft‐versus‐host disease model. J Immunol 1995; 155: 2350
   PubMed Web of Science ®Google Scholar
• Jiang Y. Z., Mavroudis D. A., Dermime S., Molldrem J., Hensel N. F., Barrett A. J. Limited usage of T‐cell receptor (TCR) Vb by T‐cells responding to chronic myelogenous leukemia (CML): implications for positively selecting and specifically enhancing the graft versus leukemia effect. (abstract). Blood 1996; 88: 243a
   Google Scholar